| Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635) |
|---|
| 01/30/2003 | CA2451392A1 Prostaglandin analogues as ep4 receptor agonists |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/29/2003 | EP1279404A1 Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| 01/29/2003 | EP1279039A1 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1) |
| 01/29/2003 | EP1278870A1 Splice variant of camp phosphodiesterase type 7 (pde7a3) |
| 01/29/2003 | EP1278869A2 Proteases |
| 01/29/2003 | EP1278859A2 Human protein kinases and protein kinase-like enzymes |
| 01/29/2003 | EP1278853A2 Listeria monocytogenes genome, polypeptides and uses |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278842A2 Dna encoding the prost 03 polypeptide |
| 01/29/2003 | EP1278838A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278774A2 Human g-protein coupled receptors |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278751A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists |
| 01/29/2003 | EP1278747A1 Pyrano, piperidino, and thiopyrano compounds and methods of use |
| 01/29/2003 | EP1278746A2 Dihydropyridine compounds and methods of use |
| 01/29/2003 | EP1278734A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
| 01/29/2003 | EP1278729A1 Benzosuberonylpiperidine compounds as analgesics |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278543A2 Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 01/29/2003 | EP1210349B1 PYRAZOLO 4,3-d]PYRIMIDINES |
| 01/29/2003 | EP1030836B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 01/29/2003 | EP1024815B1 Pharmaceutical compositions for oral administration of molecular iodine |
| 01/29/2003 | EP0572560B1 Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 01/29/2003 | CN1394141A Fulvestrant formulation |
| 01/29/2003 | CN1394140A Prostaglandin compositions and method of treatment for male erectile dysfunction |
| 01/29/2003 | CN1393444A Compound for treating impotence |
| 01/29/2003 | CN1393242A Plaster for treating mastoplasia |
| 01/29/2003 | CN1099881C Chinese medicine pill for treating male infertility |
| 01/28/2003 | US6512002 Methods of treatment for premature ejaculation in a male |
| 01/28/2003 | CA2307101C Pharmaceutical articles of manufacture comprising selective phosphodiesterase inhibitors for the treatment of sexual dysfunction |
| 01/28/2003 | CA2148839C Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 01/28/2003 | CA2127553C Peptides with organo-protective activity, process for their preparation and their use in the therapy |
| 01/28/2003 | CA2094300C Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006620A2 Linear and cyclic melanocortin receptor-specific peptides |
| 01/23/2003 | WO2003006495A2 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 01/23/2003 | WO2003006491A2 Peptide-based compounds for targeting intergin receptors |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006049A1 Gonadotropin releasing hormone antagonists in gel-forming concentrations |
| 01/23/2003 | WO2003006027A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 01/23/2003 | WO2003005999A2 Methods of treating cytokine mediated diseases |
| 01/23/2003 | WO2003005989A2 Granulates containing liposoluble substances and a process for the preparation thereof |
| 01/23/2003 | WO2003005962A2 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2003005954A2 Methods and materials for the treatment of testosterone deficiency in men |
| 01/23/2003 | WO2002088143A3 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/23/2003 | WO2002066475A3 Tricyclic androgen receptor modulator compounds |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002046138A3 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 01/23/2003 | WO2002041835A3 Estrogen receptor modulators |
| 01/23/2003 | WO2002036127A3 Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes |
| 01/23/2003 | WO2002022659A3 DISCRIMINATION BETWEEN GnRH-I AND GnRH-II |
| 01/23/2003 | WO2002003974A3 Composition comprising folic acid and zinc for improving male fertility |
| 01/23/2003 | WO2001089548A3 Pharmaceutical use of fibulin-1 |
| 01/23/2003 | WO2001083782A3 Novel proteases |
| 01/23/2003 | WO2001051472A9 New imidazole derivatives |
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018068 Vanadium (IV) metallocene complexes having spermicidal activity |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018035 Central nervous system disorders |
| 01/23/2003 | US20030018026 Preterm labor; urogenital disorders; fertility; psychological disorders |
| 01/23/2003 | US20030018018 Mixture of ethinyl estradiol and norethindron acetate |
| 01/23/2003 | US20030018013 Cardiovascular disorders; antilipemic agents; Alzheimer's disease |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017207 Compositions and methods for treating vulvovaginitis and vaginosis |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2777199A1 Methods and materials for the treatment of testosterone deficiency in men |
| 01/23/2003 | CA2453515A1 Linear and cyclic melanocortin receptor-specific peptides |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453147A1 Methods of treating cytokine mediated diseases |
| 01/22/2003 | EP1277837A2 Epididymis-specific DNA sequences and their use |
| 01/22/2003 | EP1276902A2 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276850A2 Human müllerian duct-derived epithelial cells and methods of isolation and uses thereof |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276755A1 Novel compounds |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276722A1 Naphthamidine urokinase inhibitors |
| 01/22/2003 | EP1276481A2 Daily treatment for erectile dysfunction using a pde5 inhibitor |
| 01/22/2003 | EP1276478A2 (2-aminoethyl) oxime derivatives for the treatment of depression |
| 01/22/2003 | EP1222459A4 Crystallographic structure of the androgen receptor ligand binding domain |
| 01/22/2003 | EP1165537B1 Hydroxymatairesinol in cancer prevention |
| 01/22/2003 | EP0973774B1 1,5-dihydro-pyrazolo 3,4-d]-pyrimidinone derivatives |
| 01/22/2003 | CN1391930A External medicine for curing gynaecological imflammation and its preparing method |
| 01/22/2003 | CN1099287C Medicinal composition and its use |
| 01/22/2003 | CN1099284C Aryloxy propyl amine compound for treatment of incontinence of urine |
| 01/22/2003 | CN1099282C Foaming agent fo r treating gynopathy and its preparing process |